Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
Clinical trial NCT00424606 · COMPLETED
Trial details
- NCT number
- NCT00424606
- Sponsor
- Hellenic Oncology Research Group
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2001-06-01
- Primary completion
- 2013-08-01
- Enrollment
- 658
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.